OR WAIT null SECS
September 18, 2015.
The value of the HIV treatment market will increase marginally from just over $14 billion in 2013 to $15.3 billion by 2023, GlobalData reports. This represents a CAGR rate of only 0.9% across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China.
GlobalData's report states that while the overall market size will not undergo major changes, the treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens (STRs). This shift will be most pronounced in the US, as financial austerity measures remain a primary barrier to growth in the other countries.
During the forecast period, market growth will be limited by patent expirations of several key products, such Gilead Sciences’ Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]).
Furthermore, several countries, such as Germany, China and Brazil, will promote the use of more affordable generic drugs over branded products.
See more information on the report here: PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2023